Skip to main content
Clinical Trials/ACTRN12611000495921
ACTRN12611000495921
Not yet recruiting
Phase 2

Multi-Parametric Cardiovascular Magnetic Resonance Assessment of Hypertrophic Cardiomyopathy - Therapeutic Metformin sub-study

Professor Joseph Selvanayagam0 sites120 target enrollmentMay 11, 2011

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Professor Joseph Selvanayagam
Enrollment
120
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 11, 2011
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Professor Joseph Selvanayagam

Eligibility Criteria

Inclusion Criteria

  • Hypertrophic cardiomyopathy patients aged between 18 and 75; phenotype positive (established by echocardiography or cardiac magnetic resonance scan); genotype positive for cardiac myosin binding protein\-C gene mutations or cardiac beta\-myosin heavy chain gene mutations; patients with reduced baseline PCR/ATP ratio of \<1\.7

Exclusion Criteria

  • Impaired LV systolic function (EF \<50%) as detected on echocardiography or cardiac magnetic resonance scan; history of diabetes mellitus, calculated GFR \<30mls/hr; significant derranged liver function defined as liver enzymes of 3 x ULN; current therapy with metformin or amiodarone; absolute contraindication of having MRI scan.

Outcomes

Primary Outcomes

Not specified

Similar Trials